All News

Because of the NECC Case, the nation has a much more consistent approach toward regulating and overseeing compounding pharmacies.

AACP offers a rebuttal to a Drug Topics opinion article.

New technology is helping patients, nurses, and pharmacists alike.

Vaccinations in adulthood play an important role in public health and in reducing the morbidity and mortality associated with infections.

Pete Kreckel has a love hate relationship with technology.

As the opioid crisis worsens, debates rage about the best methods to combat it.

How women are becoming more involved than ever in pharmacy.

How one opioid abuse deterrent could make it easy to identify misuse.

The U.S. market remains the largest single-country market in the world.

How value assessment tools enhance decision-making in oncology.

Xadago has been approved as a supplementary medication for patients with Parkinson's disease who are having "off" episodes or whose disease is progressing.

Why the market is expecting such significant growth (and how pharmacists can keep their patients in the huge market).

Pharmacists must find good alternative therapeutic substitutions for sodium nitroprusside in the face of price gouging and drug shortages.

Following checklists may not be what you think of when you think of the job of someone in a profession.

There is lots of room for both success and failure in the Alzheimer's drug market.

Interventions by pharmacists can help improve the results of diabetes clinical trials.

Good glucose control can help children and teens with type 1 diabetes boost their quality of life.

The first opioid taken off the shelves because of potential abuse.

A study found that pharmacy practice faculty experience high rates of emotional exhaustion.

NACDS and APhA warn that letting Americans buy foreign drugs could be disastrous.

New therapies and increased awareness lead to a large market.

Increased collaboration with physicians means better health outcomes, but what does that look like in the real world?

Reimbursement, initiation, and what pharmacists can do.

In a letter to the CMS, DIR fees take precedence

The PBM giant claims it is owed $14.5 million in fees.

Gottlieb and the FDA are being praised for their efforts, but could they be doing more?

Law curbs pharmacist hours to prevent errors due to fatigue.

Pembrolizumab gets FDA approval for cancers with a certain biomarker.